[go: up one dir, main page]

CL2016000150A1 - Compuestos y composiciones como inhibidores de la mek - Google Patents

Compuestos y composiciones como inhibidores de la mek

Info

Publication number
CL2016000150A1
CL2016000150A1 CL2016000150A CL2016000150A CL2016000150A1 CL 2016000150 A1 CL2016000150 A1 CL 2016000150A1 CL 2016000150 A CL2016000150 A CL 2016000150A CL 2016000150 A CL2016000150 A CL 2016000150A CL 2016000150 A1 CL2016000150 A1 CL 2016000150A1
Authority
CL
Chile
Prior art keywords
compounds
mek inhibitors
compositions
quinolina
heteroaril
Prior art date
Application number
CL2016000150A
Other languages
English (en)
Inventor
Gary Bock Mark
Moebitz Henrik
Kumar Panigrahi Sunil
Poddutoori Ramulu
Samajdar Susanta
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2016000150A1 publication Critical patent/CL2016000150A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPUESTOS DERIVADOS DE 7-FLUORO-8-(4-(HETEROARIL-OXI)FENIL)-1-(PIPERIDIN-4-IL)-1H-IMIDAZO[4,5-C]QUINOLINA, INHIBIDORES DE MEK; COMPOSICION FARAMCEUTICA; Y SU US EN EL TRATAMIENTO DEL CANCER
CL2016000150A 2013-08-14 2016-01-20 Compuestos y composiciones como inhibidores de la mek CL2016000150A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2418DE2013 2013-08-14
IN1686DE2014 2014-06-24

Publications (1)

Publication Number Publication Date
CL2016000150A1 true CL2016000150A1 (es) 2016-06-10

Family

ID=51844790

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000150A CL2016000150A1 (es) 2013-08-14 2016-01-20 Compuestos y composiciones como inhibidores de la mek

Country Status (33)

Country Link
US (3) US9227969B2 (es)
EP (1) EP3033343B1 (es)
JP (1) JP6473453B2 (es)
KR (1) KR102354208B1 (es)
CN (1) CN105473588B (es)
AP (1) AP2016008981A0 (es)
AU (1) AU2014307593C1 (es)
BR (1) BR112016001783B1 (es)
CA (1) CA2921300C (es)
CL (1) CL2016000150A1 (es)
CR (1) CR20160072A (es)
CU (1) CU20160020A7 (es)
DO (1) DOP2016000047A (es)
EA (1) EA029093B1 (es)
ES (1) ES2714718T3 (es)
GE (1) GEP201706725B (es)
HK (1) HK1219271A1 (es)
IL (1) IL243349A0 (es)
MX (1) MX359401B (es)
NI (1) NI201600014A (es)
PE (1) PE20160204A1 (es)
PH (1) PH12016500003A1 (es)
PL (1) PL3033343T3 (es)
PT (1) PT3033343T (es)
SG (1) SG11201510727VA (es)
SV (1) SV2016005153A (es)
TN (1) TN2015000574A1 (es)
TR (1) TR201902709T4 (es)
TW (1) TW201536782A (es)
UA (1) UA116566C2 (es)
UY (1) UY35704A (es)
WO (1) WO2015022662A1 (es)
ZA (1) ZA201509337B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
EP3125920B1 (en) 2014-04-04 2020-12-23 Del Mar Pharmaceuticals Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer
EP4477222A3 (en) 2015-01-30 2025-02-26 Biomed Valley Discoveries, Inc. Crystalline 4-(5-chloro-2-isopropylaminopyridin-4-yl)-1h-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide hydrochloride salt
CA3168216C (en) * 2015-01-30 2025-11-18 Biomed Valley Discoveries, Inc. CRYSTALIN MALONATE C21H22Cl2N4O2
ES2930050T3 (es) * 2015-06-15 2022-12-05 Asana Biosciences Llc Inhibidores heterocíclicos de ERK1 y ERK2 y su uso en el tratamiento de cáncer
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
WO2019200216A1 (en) * 2018-04-12 2019-10-17 The Methodist Hospital System Modulation of irf-4 and uses thereof
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
CN110141657B (zh) * 2019-05-17 2023-01-17 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 一种表皮生长因子脂质体及其制备方法
BR112022003514A2 (pt) 2019-09-16 2022-05-17 Novartis Ag Degradadores bifuncionais de brd9 e seus métodos de uso
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP2024521788A (ja) 2021-05-27 2024-06-04 ミラティ セラピューティクス， インコーポレイテッド 併用療法
JP2025509969A (ja) * 2022-03-24 2025-04-11 バイオメッド バレー ディスカバリーズ，インコーポレイティド Ｅｒｋのピロール阻害剤の重水素化アナログ、その合成およびその中間体
JP2025529185A (ja) * 2022-08-30 2025-09-04 パンネックス セラピューティクス インコーポレイテッド パネキシン－１調節剤及びパネキシン－１が関与する疾患の治療方法
CN117800964A (zh) * 2022-09-30 2024-04-02 四川大学 PI3K/m-TOR抑制剂及其应用
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445129A (fr) 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3453257A (en) 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3453259A (en) 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
ZA848968B (en) 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
EP0385630B1 (en) 1989-02-27 1996-11-27 Riker Laboratories, Inc. 1H-imidazo(4,5-c)Quinolin-4-amines as antivirals
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
GB8928281D0 (en) 1989-12-14 1990-02-21 Smith Kline French Lab Compounds
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5395855A (en) 1990-05-07 1995-03-07 Ciba-Geigy Corporation Hydrazones
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
DK1975181T3 (da) 1992-10-28 2011-06-06 Genentech Inc Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
EP2295415A1 (en) 1995-03-30 2011-03-16 OSI Pharmaceuticals, Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
CZ1598A3 (cs) 1995-07-06 1998-04-15 Novartis Ag Pyrrolopyrimidiny a způsoby jejich přípravy
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GEP20012442B (en) 1996-04-12 2001-05-25 Warner Lambert Co Irreversible Inhibitors of Tyrosine Kinases
CA2258548C (en) 1996-06-24 2005-07-26 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
AU716610B2 (en) 1996-08-30 2000-03-02 Novartis Ag Method for producing epothilones, and intermediate products obtained during the production process
DE69724269T2 (de) 1996-09-06 2004-06-09 Obducat Ab Verfahren für das anisotrope ätzen von strukturen in leitende materialien
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
CA2265630A1 (en) 1996-09-13 1998-03-19 Gerald Mcmahon Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CN1196698C (zh) 1996-11-18 2005-04-13 生物技术研究有限公司(Gbf) Epothilone D、E和F,其制备方法,以及作为细胞抑制剂和植物保护剂的应用
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
EP1058679B1 (en) 1998-02-25 2005-10-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues therof
BR9912938B1 (pt) 1998-08-11 2011-06-28 derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
JP2000119271A (ja) * 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
WO2000031247A2 (en) 1998-11-20 2000-06-02 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
ES2245833T5 (es) 1998-12-22 2013-07-19 Genentech, Inc. Antagonistas del factor de crecimiento celular del endotelio vascular y usos de los mismos
DE60028740T2 (de) 1999-03-30 2007-05-24 Novartis Ag Phthalazinderivate zur behandlung von entzündlichen erkrankungen
WO2002016370A1 (en) 2000-08-22 2002-02-28 Hokuriku Seiyaku Co., Ltd. 1h-imidazopyridine derivatives
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
JP2004161662A (ja) 2002-11-13 2004-06-10 Abbott Japan Co Ltd １ｈ−イミダゾキノリン誘導体
CN1747953A (zh) * 2002-12-20 2006-03-15 3M创新有限公司 芳基/杂芳基取代的咪唑并喹啉
EP1590348A1 (en) * 2002-12-20 2005-11-02 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
AU2004220534A1 (en) * 2003-03-07 2004-09-23 3M Innovative Properties Company 1-amino 1H-imidazoquinolines
CA2530452C (en) 2003-07-02 2011-07-26 F. Hoffmann-La Roche Ag Indolyl derivatives substituted with a thiazole ring and their use as ppar modulators
AR046845A1 (es) 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
CA2546117A1 (en) 2003-11-21 2005-06-16 Novartis Ag 1h-imidazoquinoline derivatives as protein kinase inhibitors
CA2559863A1 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
CA2597446A1 (en) 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2007035935A1 (en) 2005-09-23 2007-03-29 Coley Pharmaceutical Group, Inc. METHOD FOR 1H-IMIDAZO[4,5-c]PYRIDINES AND ANALOGS THEREOF
JP2009519955A (ja) 2005-12-16 2009-05-21 コーリー ファーマシューティカル グループ，インコーポレイテッド 置換されたイミダゾキノリン、イミダゾナフチリジンおよびイミダゾピリジン、組成物ならびに方法
WO2007079086A1 (en) 2005-12-28 2007-07-12 Coley Pharmaceutical Group, Inc. Pyrazoloalkyl substituted imidazo ring compounds and methods
KR101472607B1 (ko) 2007-02-20 2014-12-15 노파르티스 아게 지질 키나제 및 ｍＴＯＲ의 이중 억제제로서의 이미다조퀴놀린
US8841462B2 (en) 2008-07-01 2014-09-23 Robert A. Heald Bicyclic heterocycles as MEK kinase inhibitors
KR20110028651A (ko) 2008-07-11 2011-03-21 노파르티스 아게 (ａ) 포스포이노시타이드 3-키나제 억제제 및 (ｂ) ｒａｓ/ｒａｆ/ｍｅｋ 경로의 조절제의 조합물
CA2735932C (en) * 2008-09-30 2013-07-09 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
JP5466767B2 (ja) 2009-11-04 2014-04-09 ノバルティス アーゲー Ｍｅｋ阻害剤として有用なヘテロ環式スルホンアミド誘導体
JP5863058B2 (ja) * 2010-05-17 2016-02-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １Ｈ−イミダゾ［４，５−ｃ］キノリン
BR112013001088A2 (pt) 2010-07-16 2016-05-24 Piramal Entpr Ltd "derivados substituídos como inibidores a quinase de imidazoquinolina"
AU2011301518B2 (en) 2010-09-16 2014-07-03 Hutchison Medipharma Limited Fused heteroaryls and their uses
WO2012077031A1 (en) * 2010-12-06 2012-06-14 Piramal Life Sciences Limited Substituted imidazoquinoline derivatives
AU2012318694B2 (en) 2011-10-04 2016-12-22 Janus Biotherapeutics, Inc. Novel imidazole quinoline-based immune system modulators
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
BR112014029338A2 (pt) 2012-05-31 2017-06-27 Bayer Pharma AG biomarcadores para determinação da resposta eficaz dos tratamentos de pacientes com carcinoma hepatocelular (hcc)
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK

Also Published As

Publication number Publication date
EA029093B1 (ru) 2018-02-28
US20160136150A1 (en) 2016-05-19
WO2015022662A1 (en) 2015-02-19
IL243349A0 (en) 2016-02-29
SG11201510727VA (en) 2016-02-26
DOP2016000047A (es) 2016-08-31
MX2016001980A (es) 2016-06-21
PE20160204A1 (es) 2016-04-27
ZA201509337B (en) 2017-04-26
MX359401B (es) 2018-09-27
US10011599B2 (en) 2018-07-03
UA116566C2 (uk) 2018-04-10
TW201536782A (zh) 2015-10-01
CA2921300A1 (en) 2015-02-19
CR20160072A (es) 2016-05-09
CN105473588B (zh) 2018-06-05
US20170183348A1 (en) 2017-06-29
KR102354208B1 (ko) 2022-01-20
JP6473453B2 (ja) 2019-02-20
TR201902709T4 (tr) 2019-03-21
GEP201706725B (en) 2017-08-25
TN2015000574A1 (en) 2017-04-06
EP3033343B1 (en) 2018-12-05
BR112016001783A2 (pt) 2017-08-01
HK1219271A1 (zh) 2017-03-31
NI201600014A (es) 2016-03-10
AU2014307593C1 (en) 2016-11-24
ES2714718T3 (es) 2019-05-29
US20150051209A1 (en) 2015-02-19
PT3033343T (pt) 2019-03-21
PL3033343T3 (pl) 2019-06-28
BR112016001783B1 (pt) 2022-07-05
CN105473588A (zh) 2016-04-06
SV2016005153A (es) 2016-11-21
PH12016500003A1 (en) 2016-03-28
KR20160039203A (ko) 2016-04-08
AU2014307593B2 (en) 2016-07-21
AU2014307593A1 (en) 2016-02-04
AP2016008981A0 (en) 2016-01-31
JP2016530263A (ja) 2016-09-29
UY35704A (es) 2015-03-27
US9629836B2 (en) 2017-04-25
EA201690386A1 (ru) 2016-06-30
CA2921300C (en) 2021-06-29
EP3033343A1 (en) 2016-06-22
US9227969B2 (en) 2016-01-05
CU20160020A7 (es) 2017-02-02

Similar Documents

Publication Publication Date Title
CL2016000150A1 (es) Compuestos y composiciones como inhibidores de la mek
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
CL2015000829A1 (es) Inhibidores de histona desmetilasas
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
MX2016015743A (es) Compuestos de ciclopropilamina como inhibidores de histona demetilasa.
CL2015000711A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona como inhibidores de notch; composicion farmaceutica y uso en el tratamiento del cancer.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
MX383590B (es) Inhibidores de kdm1a para el tratamiento de enfermedades.
MX390537B (es) Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm
PH12017502141A1 (en) Compounds and their methods of use
MX376008B (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
TR201816379T4 (tr) DNA-PK inhibitörleri.
CL2015003280A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
MX2016008131A (es) Compuestos heterociclos biciclicos y sus usos en terapia.
CL2015002932A1 (es) Inhibidores de proteína quinasa
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
UY34648A (es) Amidas como inhibidores de pim
PE20151023A1 (es) Triazolopirazinas
MX373129B (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.